Login / Signup

N,N-Diformylmescaline: A novel analogue of mescaline detected in Queensland.

Ryan GallagherMaddison G McLaughlinKaren BlakeyUrs D WermuthSue BoydJenny McGowan
Published in: Drug testing and analysis (2022)
N,N-Diformylmescaline, a novel analogue of mescaline, has recently been detected in Australia in two unrelated seizures. To confirm the identification, a three-step synthesis from 3,4,5-trimethoxyphenylacetic acid was devised. However, purification of the final product proved problematic with the compound prone to degradation in solution. Analysis of the compound by LC-MS indicated that the compound was unstable under acidic and basic conditions, breaking down to N-formylmescaline. Further degradation to mescaline was observed when the compound was dissolved in hydrochloric acid for an extended period of time suggesting that N,N-diformylmescaline may be a prodrug for mescaline. The GC-MS, NMR and FTIR data for the seized compound are presented along with details of the synthesis and studies of the compound's stability in solution.
Keyphrases
  • mass spectrometry
  • drug delivery
  • organic matter
  • drug release
  • case control